Results 161 to 170 of about 29,491 (205)
Some of the next articles are maybe not open access.
2009
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Physics Today, 2000
Each year in the US, about 200 000 patients receive therapy with radionuclides, most commonly in the form of sealed sources for treating gynecological and head and neck cancers and radiopharmaceuticals for treating thyroid cancer. Known as brachytherapy, this kind of treatment has attracted a resurgence of interest in the medical world, primarily ...
Bert M. Coursey, Ravinder Nath
openaire +1 more source
Each year in the US, about 200 000 patients receive therapy with radionuclides, most commonly in the form of sealed sources for treating gynecological and head and neck cancers and radiopharmaceuticals for treating thyroid cancer. Known as brachytherapy, this kind of treatment has attracted a resurgence of interest in the medical world, primarily ...
Bert M. Coursey, Ravinder Nath
openaire +1 more source
Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals, 2013Radionuclide therapy (RNT) based on the concept of delivering cytotoxic levels of radiation to disease sites is one of the rapidly growing fields of nuclear medicine. Unlike conventional external beam therapy, RNT targets diseases at the cellular level rather than on a gross anatomical level.
Ashutosh, Dash +2 more
openaire +2 more sources
Radionuclide Therapy for Neuroendocrine Tumors
Current Oncology Reports, 2017Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of ...
CIVES, MAURO, Strosberg, Jonathan
openaire +3 more sources
Radionuclides and therapy of thyroid cancer
Nuclear Medicine Communications, 1993The majority of thyroid carcinomas are removed surgically. The appropriate surgical technique is still debated. After surgery the amount of residual thyroid or tumour and the presence of local or distant metastases is often in doubt, particularly if it is not detectable clinically. Therefore, methods for determining the presence of disease or the later
O'Doherty, M J, Nunan, T O, Croft, D N
openaire +2 more sources
Targeted Radionuclide Therapy of Melanoma
Seminars in Nuclear Medicine, 2016An estimated 60,000 individuals in the United States and 132,000 worldwide are yearly diagnosed with melanoma. Until recently, treatment options for patients with stages III-IV metastatic disease were limited and offered marginal, if any, improvement in overall survival. The situation changed with the introduction of B-RAF inhibitors and anti-cytotoxic
Abdullah, Norain, Ekaterina, Dadachova
openaire +2 more sources
Radionuclide therapy of adrenal tumors
Journal of Surgical Oncology, 2012AbstractAdrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I‐131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu‐177 or Y‐90 radiolabeled somatostatin analogs.
Jorge A, Carrasquillo +2 more
openaire +2 more sources
American Journal of Clinical Oncology, 1989
This book presents a survey of uses of parenterally administered radionuclides as therapeutic sources and concentrates on both the basic considerations of each mode of use as well as the clinical results and experiences. This volume provides a source of information for the clinical physician and scientist involved in therapy, and describes current ...
openaire +1 more source
This book presents a survey of uses of parenterally administered radionuclides as therapeutic sources and concentrates on both the basic considerations of each mode of use as well as the clinical results and experiences. This volume provides a source of information for the clinical physician and scientist involved in therapy, and describes current ...
openaire +1 more source
The use of radionuclides for tumor therapy
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1986The successful use of radionuclides for tumor therapy depends to a major extent on the ability to achieve a high concentration of radioactivity in the tumor relative to other radiosensitive organs not involved by tumor, such as bone marrow, intestinal mucosa, liver, and kidneys.
R A, Fawwaz +3 more
openaire +2 more sources
Recent advances in radionuclide therapy
Seminars in Nuclear Medicine, 2001A variety of radionuclides continue to be investigated and/or clinically used for different therapeutic applications in nuclear medicine. The choice of a particular radionuclide with regard to appropriate emissions, linear energy transfer, and physical half-life is dictated to a large extent by the character of the disease (eg, solid tumor or ...
S, Srivastava, E, Dadachova
openaire +2 more sources